Acute appendicitis is a rare diagnosis of acute abdomen in neonates which is associated with high mortality due to late diagnosis. Here, we presented a case of acute neonatal appendicitis in a 6-year-old full-term infant with Down syndrome and pulmonary atresia with ventricular septal defect. The patient underwent surgery and postoperative critical care. However, he died on postoperative day 5 due to worsening sepsis and decompensated hemodynamic instability.
Objective This study aims to explore the short-term results of hepatectomy with Takasaki’s technique using Sonastar ultrasonic aspiration system. Materials and Methods We retrospectively examined data of 58 patients who underwent hepatectomy with Takasaki’s technique using Sonastar ultrasonic aspiration system at Hue Central Hospital from 01/2018 to 02/2021. Results The mean age was 60.7 ± 10.5 years (25–80) and the male/female ratio was 6:1. Patients with solitary tumor accounted for 79%; 68.4% had tumor size greater than 5 cm. Pringle maneuver was used in 57.9%, while selective right or left Glissonean pedicle occlusion was used in 69.0% and 32.8%, respectively. Final transection surface reinforcement was achieved by Surgicel and BioGlue in 78.9% and 21.5% of cases, respectively. Major liver resection accounted for 73.7%. The mean parenchymal transection time was 50 (45–110) minutes, while mean total operative time was 125 (90–280) minutes. Mean operative blood loss was 250 (150–650) mL. Mean post-operative hospital stay was 8 days (7–23). Post-operative complication rate was 15.9% and mortality rate was 1.7%. Conclusion Hepatectomy using Takasaki technique with Sonastar ultrasonic aspiration system is safe, effective, allowing an anatomical resection with sufficient safety margin and resulting in low complication rates (liver failure, biliary leakage) and good survival outcomes.
Background: Hepatocellular carcinoma (HCC) is one of the most common cancer and ranks third in terms of cancer related deaths. The majority of patients are not eligible for curative treatment because of local or distal progression of tumor. RFA treatment following TACE has some advantages over TACE alone. The purpose of this study was to evaluate the effectiveness and survival benefits of the TACE+RFA approach to the management of unresectable HCCs in Hue Central Hospital, Vietnam. Methods: A prospective, cohort study on 60 patients, diagnosed with unresectable HCCs and treated with TACE combined with RFA at Hue Central Hospital from 1/2016 – 1/2019. All clinical and paraclinical data and adverse effects of each treatment, tumor response rate assessed by m-RECIST criteria, survival rate and other adverse events from the first treatment were documented. Results: There were no major complications after combined therapy except for two cases (1.4%) of liver failure treated successfully with conservative therapy. Tumor control rate (CR+PR) at three months after the last treatment was 81.6%. All patients were followed-up closely after treatment and additional treatments were decided based on imaging and laboratory results. The mean follow-up time was 19.3 (4 – 30) months. The 1-year and 2-year survival rates were 71.7% and 58.3%, respectively. Conclusion: Combination therapy with TACE and RFA is an effective, safe and feasible option for patients with unresectable HCCs. Key words: Hepatocellular carcinoma (HCC), transarterial chemoembolisation (TACE), radiofrequency ablation (RFA) 1
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.